KJ-C2527

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameKJ-C2527
Drug Alias NameKJ-C2527
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunostimulantsClaudin 18 protein modulatorsT lymphocytes stimulants
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesCarsgen Therapeutics ltd
China Registration ClassN/A

Develop Information

Active CompaniesCarsgen Therapeutics ltd
Inactive CompaniesN/A
Active IndicationsStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A